Novo Nordisk's CEO Has a Comeback Plan
When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night.
Further Listening:
- Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More description
When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night.
Further Listening:
- Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.